Orion Oyj (ORINF) reports significant sales and profit growth, driven by innovative medicines and sustainability efforts, while adjusting its financial outlook for the year.

Wondering whether Orion Oyj at €68.70 is still offering value or if most of the opportunity is already reflected in the price? This review walks through what the market is currently paying for the shares and how that stacks up against several valuation checks. The stock has a mixed recent return profile, with a 0.8% move over the last week, a 7.5% decline over the last month, but gains of 8.5% year to date and 30.9% over the past year, and 77.2% and 139.7% over the last 3 and 5 years...

Orion Oyj overview and recent share performance Orion Oyj (HLSE:ORNBV) has drawn attention after recent share price moves, with a 1 day return of 2.19%, a 7 day gain of 5.02% and a past month decline of 5.15%. See our latest analysis for Orion Oyj. Zooming out, Orion Oyj’s 14.74% 90 day share price return sits alongside a 35.63% 1 year total shareholder return and a 143.81% 5 year total shareholder return, which points to momentum that has been building over time. If Orion’s recent move has...

Orion Oyj (HLSE:ORNBV) reported record financial performance for 2025, including all time high net sales and operating profit. The company highlighted significant R&D progress, with new approvals, partnerships and substantial milestone income during the year. Two Board members have informed the company they will not seek re election at the upcoming Annual General Meeting, prompting expected changes in Board composition. For investors watching the Nordic pharmaceuticals space, Orion Oyj sits...

Orion Oyj has reported past fourth-quarter 2025 sales of €695.3 million and net income of €260.5 million, alongside a proposal to pay a €1.80 per share dividend in 2026 in two instalments following an all-time high year for net sales and operating profit. An additional €180 million Nubeqa milestone from Bayer and progress in oncology-focused R&D, paired with a new long-term incentive program tied to financial, pipeline and ESG targets, underline how Orion is aligning management rewards with...

Orion Oyj (ORINY) reports robust Q4 performance with significant revenue growth, strategic milestones, and a positive outlook for 2026.

Without a specific news headline driving attention, Orion Oyj (HLSE:ORNBV) still stands out today as investors weigh its recent share performance, profitability profile, and role in the broader pharmaceuticals and biotech space. See our latest analysis for Orion Oyj. At a share price of €72.55, Orion Oyj has seen strong momentum recently, with a 30 day share price return of 14.61% and a 1 year total shareholder return of 42.02%. This suggests investors have been reassessing its earnings power...

Event context and recent share performance Orion Oyj (HLSE:ORNBV) has recently attracted investor attention after a period of strong share performance, with the stock showing positive total returns over the past year and multi year periods. See our latest analysis for Orion Oyj. The latest 1 day share price return of 12.03% and 30 day share price return of 14.78% suggest momentum has recently picked up, sitting alongside a 1 year total shareholder return of 57.62% and 5 year total shareholder...

Orion Oyj (HLSE:ORNBV) has quietly put up a strong year in the background, with the share price up about 40% year to date, even after a recent 8% pullback over the past 3 months. See our latest analysis for Orion Oyj. With the share price now at $60.9 and a robust year to date share price return of almost 40%, recent weakness over the last quarter looks more like a breather than a reversal, especially given the near 43% one year total shareholder return and strong five year compounding. If...